Nanocarriers in controlled drug delivery: An overview

Controlled drug delivery systems are developed to release therapeutic agents at predetermined rates and targeted sites to enhance treatment efficacy while minimizing adverse effects. Conventional dosage forms often exhibit limitations such as poor solubility, rapid drug degradation, fluctuating plasma concentrations, and non-specific distribution, which can reduce therapeutic outcomes. Nanocarriers have emerged as an advanced solution to these challenges due to their ability to encapsulate drugs, protect them from physiological degradation, and improve pharmacokinetic behavior. Engineered from lipids, polymers, proteins, and inorganic materials, nanocarriers offer improved stability, prolonged circulation time, and enhanced penetration across biological barriers.Nanocarriers, typically ranging from 1-1000 nm in size, enable controlled and site-specific drug release through mechanisms such as diffusion, degradation, swelling, and stimuli-responsive triggers. Their surfaces can be functionalized with ligands or antibodies to achieve active targeting, resulting in higher drug accumulation at diseased tissues and reduced systemic toxicity. Various preparation methods including solvent evaporation, nanoprecipitation, emulsification, ionic gelation, and high-pressure homogenization are employed to produce stable formulations with desired release profiles. Proper characterization techniques such as particle size analysis, zeta potential measurement, drug entrapment efficiency, morphology evaluation, and in-vitro release studies ensure formulation quality and safety.The broad applications of nanocarriers in cancer therapy, antimicrobial treatment, ocular and brain drug delivery, gene therapy, vaccine development, and personalized medicine highlight their growing importance in modern pharmaceutics. Despite challenges such as high production costs, stability concerns, and regulatory complexities, recent advances in smart and theranostic nanocarriers have significantly expanded their clinical potential. Future research focusing on biocompatible materials, scalable manufacturing, and long-term safety is expected to accelerate their clinical translation. Overall, nanocarriers represent a transformative approach in controlled drug delivery, offering safer, more efficient, and patient-centric therapeutic strategies.